Phenotypic and molecular characterization of Acinetobacter clinical isolates obtained from inmates of California correctional facilities

Journal of Clinical Microbiology

Volumn 49, Issue 6, 2011, Pages 2121-2131

  Golanbar, Galarah D ^a   Lam, Christopher K ^a   Chu, Yi Ming ^a   Cueva, Carla ^a   Tan, Stephanie W ^a   Silva, Isba ^a   Xu, H Howard ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 NAPHTHYL)PIPERAZINE; 2 NAPHTHYLAMINE; AMIKACIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXYCYCLINE; MEROPENEM; MINOCYCLINE; PIPERACILLIN; POLYMYXIN B; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER BAYLYI; ACINETOBACTER CALCOACETICUS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA SEQUENCE; FEMALE; HUMAN; INTEGRON; MALE; MULTIDRUG RESISTANCE; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PRISON; PRISONER; SPECIES IDENTIFICATION; UNITED STATES;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CALIFORNIA; CLUSTER ANALYSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; INTEGRONS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; PRISONS; YOUNG ADULT;

ACINETOBACTER; ACINETOBACTER BAUMANNII;

EID: 79957438704     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02373-10     Document Type: Article

References (79)

1. Akasaka, T., M. Tanaka, A. Yamaguchi, and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45:2263-2268.
2. Akers, K. S., et al. 2009. Tetracycline susceptibility testing and resistance genes in isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex from a U.S. military hospital. Antimicrob. Agents Chemother. 53:2693-2695.
3. Azim, A., et al. 2010. Epidemiology of bacterial colonization at ICU admission with emphasis on extended-spectrum beta-lactamases (ESBL) and metallo-beta-lactamase (MBL) producing gram-negative bacteria-an Indian experience. J. Med. Microbiol. 59:955-960.
4. Baillargeon, J., M. F. Kelley, C. T. Leach, G. Baillargeon, and B. H. Pollock. 2004. Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin. Infect. Dis. 38:e92-e95.
5. Bergogne-Bérézin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.
6. California Department of Corrections and Rehabilitation. 2008. California prisoners and parolees 2008. California Department of Corrections and Rehabilitation, Sacramento, CA.
7. Chang, H. C., et al. 2005. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J. Clin. Microbiol. 43:1632-1639.
8. Chen, M. Z., et al. 2001. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 120:1072-1077.
9. Chuang, Y. C., et al. 2011. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin. Infect. Dis. 52:352-360.
10. CLSI. 2006. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. M100-S16, 16th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Coban, A. Y., A. K. Guney, Y. Tanriverdi Cayci, and B. Durupinar. 2010. Effect of 1-(1-naphtylmethyl)-piperazine, an efflux pump inhibitor, on antimicrobial drug susceptibilities of clinical Acinetobacter baumannii isolates. Curr. Microbiol. 62:508-511.
12. David, M. Z., C. Mennella, M. Mansour, S. Boyle-Vavra, and R. S. Daum. 2008. Predominance of methicillin-resistant Staphylococcus aureus among pathogens causing skin and soft tissue infections in a large urban jail: risk factors and recurrence rates. J. Clin. Microbiol. 46:3222-3227.
13. Deger, G. E., and D. W. Quick. 2009. The enduring menace of MRSA: incidence, treatment, and prevention in a county jail. J. Correct Health Care 15:174-178.
14. Dent, L. L., D. R. Marshall, S. Pratap, and R. B. Hulette. 2010. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect. Dis. 10:196.
15. Di Popolo, A., M. Giannouli, M. Triassi, S. Brisse, and R. Zarrilli. 2011. Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin. Microbiol. Infect. 17:197-201.
16. Falagas, M. E., E. A. Karveli, I. Kelesidis, and T. Kelesidis. 2007. Community-acquired Acinetobacter infections. Eur. J. Clin. Microbiol. Infect. Dis. 26:857-868.
17. Gales, A. C., et al. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. 32(Suppl. 2):S104-S113.
18. Gu, B., et al. 2007. Prevalence and characterization of class I integrons among Pseudomonas aeruginosa and Acinetobacter baumannii isolates from patients in Nanjing, China. J. Clin. Microbiol. 45:241-243.
19. Hamouda, A., and S. G. Amyes. 2004. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J. Antimicrob. Chemother. 54:695-696.
20. Han, H. L., et al. 2008. Identification of an atypical integron carrying an IS26-disrupted aadA1 gene cassette in Acinetobacter baumannii. Int. J. Antimicrob. Agents 32:165-169.
21. Higgins, P. G., C. Dammhayn, M. Hackel, and H. Seifert. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65:233-238.
22. Hornsey, M., et al. 2010. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J. Antimicrob. Chemother. 65:1589-1593.
23. Huang, X. Z., et al. 2010. Genotypic and phenotypic correlations of multidrug resistant Acinetobacter baumannii-calcoaceticus complex strains isolated from patients at the National Naval Medical Center. J. Clin. Microbiol. 48:4333-4336.
24. Hujer, K. M., et al. 2006. Analysis of antibiotic resistance genes in multi-drug resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 50:4114-4123.
25. Jung, J. Y., et al. 2010. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect. Dis. 10:228.
26. Kallen, A. J., and A. Srinivasan. 2010. Current epidemiology of multidrug-resistant gram-negative bacilli in the United States. Infect. Control Hosp. Epidemiol. 31(Suppl. 1):S51-S54.
27. Kang, G., et al. 2010. Mortality associated with Acinetobacter baumannii complex bacteremia among patients with war-related trauma. Infect. Control Hosp. Epidemiol. 31:92-94.
28. Karah, N., et al. 2011. Species identification and molecular characterization of Acinetobacter spp. blood culture isolates from Norway. J. Antimicrob. Chemother. 66:738-744.
29. Karlowsky, J. A., et al. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688. (Pubitemid 36548554)
30. Lee, J. H., et al. 2007. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. J. Antimicrob. Chemother. 59:633-639.
31. Lee, J. K., Y. S. Lee, Y. K. Park, and B. S. Kim. 2005. Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol. Immunol. 49:647-653.
32. Lee, N. Y., et al. 2010. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J. Infect. 61:219-227.
33. Lee, Y. T., et al. 2009. Gene cassette arrays, antibiotic susceptibilities, and clinical characteristics of Acinetobacter baumannii bacteremic strains harboring class 1 integrons. J. Microbiol. Immunol. Infect. 42:210-219.
34. Leung, W. S., et al. 2006. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 129:102-109.
35. Lévesque, C., L. Piche, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185-191.
36. Li, J., et al. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950.
37. Lin, Y. C., et al. 2010. Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. Antimicrob. Agents Chemother. 54:2078-2084.
38. Ling, M. L., A. Ang, M. Wee, and G. C. Wang. 2001. A nosocomial outbreak of multiresistant Acinetobacter baumannii originating from an intensive care unit. Infect. Control Hosp. Epidemiol. 22:48-49.
39. Long, Y. B., et al. 2009. Persistence of multiple antibiotic resistant strains of Acinetobacter baumannii carrying class 1 integron in a hospital setting. Microb. Drug Resist. 15:167-172.
40. Lowy, F. D., et al. 2007. Staphylococcus aureus colonization and infection in New York State prisons. J. Infect. Dis. 196:911-918.
41. Martín, A., et al. 2007. Molecular, epidemiological and infectivity characterisation of a Mycobacterium tuberculosis strain prevalent in Madrid. Clin. Microbiol. Infect. 13:1210-1213.
42. McDonnell, D. D., V. Levy, and T. J. Morton. 2009. Risk factors for Chlamydia among young women in a northern California juvenile detention facility: implications for community intervention. Sex Transm. Dis. 36:S29-S33.
43. Moubareck, C., S. Bremont, M. C. Conroy, P. Courvalin, and T. Lambert. 2009. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob. Agents Chemother. 53:3579-3581.
44. Nagano, N., Y. Nagano, C. Cordevant, N. Shibata, and Y. Arakawa. 2004. Nosocomial transmission of CTX-M-2 beta-lactamase-producing Acinetobacter baumannii in a neurosurgery ward. J. Clin. Microbiol. 42:3978-3984.
45. Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:5853-5859. (Pubitemid 26337766)
46. Ong, C. W., et al. 2009. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. Respirology 14:1200-1205.
47. Ozaki, T., et al. 2009. Community-acquired Acinetobacter baumannii meningitis in a previously healthy 14-month-old boy. J. Infect. Chemother. 15: 322-324.
48. Pagès, J. M., M. Masi, and J. Barbe. 2005. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol. Med. 11:382-389.
49. Pannek, S., et al. 2006. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J. Antimicrob. Chemother. 57:970-974.
50. Partridge, S. R., G. Tsafnat, E. Coiera, and J. R. Iredell. 2009. Gene cassettes and cassette arrays in mobile resistance integrons. FEMS Microbiol. Rev. 33:757-784.
51. Peleg, A. Y., et al. 2007. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 59:128-131.
52. Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
53. Ploy, M. C., F. Denis, P. Courvalin, and T. Lambert. 2000. Molecular characterization of integrons in Acinetobacter baumannii: description of a hybrid class 2 integron. Antimicrob. Agents Chemother. 44:2684-2688.
54. Ploy, M. C., T. Lambert, J. P. Couty, and F. Denis. 2000. Integrons: an antibiotic resistance gene capture and expression system. Clin. Chem. Lab. Med. 38:483-487.
55. Ramirez, M. S., and M. E. Tolmasky. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat. 13:151-171.
56. Recchia, G. D., and R. M. Hall. 1997. Origins of the mobile gene cassettes found in integrons. Trends Microbiol. 5:389-394.
57. Sáenz, Y., M. Zarazaga, L. Brinas, F. Ruiz-Larrea, and C. Torres. 2003. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals. J. Antimicrob. Chemother. 51:1001-1005.
58. Sengstock, D. M., et al. 2010. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin. Infect. Dis. 50:1611-1616.
59. Shaw, K. J., P. N. Rather, R. S. Hare, and G. H. Miller. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57:138-163.
60. Srinivasan, V. B., et al. 2009. Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, U. S. A. Ann. Clin. Microbiol. Antimicrob. 8:21.
61. Tenover, F. C., et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
62. Turabelidze, G., et al. 2006. Personal hygiene and methicillin-resistant Staphylococcus aureus infection. Emerg. Infect. Dis. 12:422-427.
63. Turton, J. F., S. N. Gabriel, C. Valderrey, M. E. Kaufmann, and T. L. Pitt. 2007. Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii. Clin. Microbiol. Infect. 13:807-815.
64. Turton, J. F., J. Shah, C. Ozongwu, and R. Pike. 2010. Incidence of Acinetobacter species other than A. baumannii among clinical isolates of Acinetobacter: evidence for emerging species. J. Clin. Microbiol. 48:1445-1449.
65. Valdezate, S., A. Vindel, A. Echeita, F. Baquero, and R. Canto. 2002. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrob. Agents Chemother. 46:665-671.
66. Valencia, R., et al. 2009. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30:257-263.
67. Valentine, S. C., et al. 2008. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J. Clin. Microbiol. 46:2499-2507.
68. van den Broek, P. J., et al. 2006. Epidemiology of multiple Acinetobacter outbreaks in The Netherlands during the period 1999-2001. Clin. Microbiol. Infect. 12:837-843.
69. van den Broek, P. J., et al. 2009. Endemic and epidemic Acinetobacter species in a university hospital: an 8-year survey. J. Clin. Microbiol. 47:3593-3599.
70. Van Looveren, M., and H. Goossens. 2004. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin. Microbiol. Infect. 10:684-704.
71. Vila, J., S. Marti, and J. Sanchez-Cespedes. 2007. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother. 59:1210-1215.
72. Vila, J., J. Ruiz, P. Goni, and T. Jimenez de Anta. 1997. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J. Antimicrob. Chemother. 39:757-762.
73. Vila, J., J. Ruiz, P. Goni, A. Marcos, and T. Jimenez de Anta. 1995. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 39:1201-1203.
74. von Dolinger de Brito, D., E. J. Oliveira, V. O. Abdallah, A. L. da Costa Darini, and P. P. Filho. 2005. An outbreak of Acinetobacter baumannii septicemia in a neonatal intensive care unit of a university hospital in Brazil. Braz. J. Infect. Dis. 9:301-309.
75. Wang, H., et al. 2007. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob. Agents Chemother. 51:4022-4028.
76. Wisplinghoff, H., et al. 2003. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 51:177-180.
77. Wyeth. 2005. Tygacil product insert. http://www.wyeth.com/hcp/tygacil/ prescribing. Wyeth, Madison, NJ.
78. Zapor, M. J., and K. A. Moran. 2005. Infectious diseases during wartime. Curr. Opin. Infect. Dis. 18:395-399.
79. Zbinden, A., E. C. Bottger, P. P. Bosshard, and R. Zbinden. 2007. Evaluation of the colorimetric VITEK 2 card for identification of gram-negative non-fermentative rods: comparison to 16S rRNA gene sequencing. J. Clin. Microbiol. 45:2270-2273.